All In Biotech

Drug Trial Radar · NCT06609005

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

A Phase 1 and Phase 2, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jan 23, 2025

Primary completion

Jan 17, 2028

Study completion Jan 17, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.

Conditions

  • Advanced Metastatic Castration Resistant Prostate Cancer

Interventions

  • INV-9956Drug

    INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Maximum tolerated dose (MTD)Time frame: Within first 28 days of treatment
  2. Phase 1: Recommended dose range (RDR)Time frame: 12 months
  3. Phase 2: Evaluate Radiographic progression-free survival (rPFS)Time frame: 12 months
  4. Phase 2: Evaluate overall response rate (ORR)Time frame: 12 months

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona · Recruiting

  • Hoag Family Cancer Institute

    Newport Beach, California · Recruiting

  • UC Irvine Medical Center

    Orange, California · Recruiting

  • Next Oncology - Houston

    Houston, Texas · Recruiting

  • UT Health

    San Antonio, Texas · Recruiting

  • NEXT Oncology

    Fairfax, Virginia · Recruiting

  • Summit Cancer Centers

    Spokane, Washington · Recruiting

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • The First People's Hospital of Foshan

    Foshan, Guangdong, China · Not yet recruiting

  • He'nan Cancer Hospital

    Zhengzhou, He'Nan, China · Recruiting

  • Hu'nan Cancer Hospital

    Changsha, Hu'Nan, China · Not yet recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • Shandong Cancer Hospital

    Ji'nan, Shandong, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Hubei, Wuhan, China · Not yet recruiting

  • The First Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.